cyrilzakka/clinical-trials huggingface dataset:
Clinical Studies of the Effects of Extracorporeal Membrane Oxygenation for Severe ARDS Mortality

Acute respiratory distress syndrome (acute respiratory distress syndrome, ARDS) fatality rate can be as high as 20% -41%, once progress is severe of ARDS, mortality rose to 90%, the main cause of death was refractory hypoxemia. Mechanical ventilation as the main measure to improve hypoxemia cannot correct all hypoxemia and relating complications of mechanical ventilation, mechanical ventilation in the treatment of severe ARDS has gradually been challenged. Extracorporeal membrane oxygenation（ECMO) technology matures, so that clinicians have more choices in the face of hypoxemia, and with the deepening understanding of ECMO, ECMO may become severe ARDS first-line treatment. Currently, ECMO therapy has been recognized by the majority of medical workers. Therefore, we assume that accurately grasping the ECMO indications and standardizing the implementation of treatment can significantly improve the prognosis, shorter hospital stays, lower hospitalization costs.


Eligibility Criteria:
Inclusion Criteria:

(1) age 18-70 years; (2) severe respiratory dysfunction (Murry score ≥ 3 points or clinical optimized ventilation conditions pH remains \<7.2 patients); (3) PaCO2/FiO2 \<100mmHg; (4) plateau pressure \>30cmH2O more than 6h，duration of no more than seven days; (5) with severe respiratory dysfunction etiology reversible.

Exclusion Criteria:

(1) high levels pressure mechanical ventilation (PEEP\> 15-20cmH2O and / or Pplat\> 35-40cmH2O) over 7 days; (2) continued to receive high concentrations of oxygen (FiO2\> 80%) is more than 7 days; (3) severe active bleeding; (4) within 24 hours of the surgery or head injury with intracranial bleeding; (5) a variety of serious irreversible state; (6) malignancy; (7) progressive pulmonary fibrosis; (8) can not surgical problems; (9) due to cardiac dysfunction leading to ARDS.
Omega-3 Supplementation for Smell Dysfunction

Omega-3 supplementation has been shown to have neuroprotective and potentially anti-inflammatory properties in both central and peripheral nerve injuries. The investigators are studying to see if omega-3 supplementation will affect olfactory (smell) function in patients with olfactory dysfunction following endoscopic removal of pituitary tumors.


Eligibility Criteria:
Inclusion Criteria:

* sellar/parasellar tumor scheduled to undergo endoscopic transnasal transsphenoidal resection
* 18 years of age or older
* English speaking

Exclusion Criteria:

* Currently using blood thinning agents (aside from NSAIDs or cardioprotective ASA)
* elevated AST, ALT, or alk phos \>10% outside of normal range, if randomized to omega-3 group
* diabetes, if randomized to omega-3 group and not already on omega-3 prescribed by another provider
* unable to provide informed consent due cognitive deficiencies
Mandibular Slotplates

A new osteosynthesis system for orthognathic surgery was proposed.This system allows small intra-operative adjustments of the bone fragments during the osteosynthesis phase of the operation (also known as the slot principle). Another possible advantage are the slant screw holes with chamfered ridges allowing easy placements of the screws via the small incision wound without undercuts in between the plate and the screwheads.

Initial slotplates were developed for Le Fort I osteotomies, zygoma 'sandwich 'osteotomies and genioplasties. Those plates allowed for the slot principle to be performed during orthognathic surgery. Mandibular slotplates for bilateral sagittal split osteotomy (BSSO) were recently designed. The aim of the study is to evaluate their clinical usefulness and the applicability of the slot principle with these plates in BSSO.

Eligibility Criteria:
Inclusion Criteria:

• Patients undergoing single osteotomy BSSO surgery

Exclusion Criteria:

• Concomitant surgeries at the same time.
The Effectiveness of Continuous Glucose Monitoring in Diabetes Treatment for Infants and Young Children

The purpose of this study is to see if the use of a real-time glucose sensor improves diabetes control in young children (less than 4 years old) with Type I diabetes when they are initiated on insulin pump therapy.

A randomized controlled clinical trial involving patients 0-3 yrs old with type 1 diabetes. After successful screening the subjects will be randomized into one of two groups: a CSII group alone and a CSII group + Real Time Sensor Augmentation group (RTSA) group. The CSII group will serve as the control for the CSII+RTSA group. The trial will last for one year.

Eligibility Criteria:
Inclusion Criteria:

* Children less than 4 years of age with Type I diabetes for at least 3 months

Exclusion Criteria:

* Children greater than 4 years of age
* Monogenic diabetes
Meaning-based Group Counselling for Bereavement

Given that individuals in bereavement tend to experience substantial psychological distress in the first two years following loss, individuals seeking psychological support will need appropriate services grounded in sound empirical scholarship. There is a lack of studies assessing bereavement groups, despite groups being one of the most common forms by which such services are offered. The prominent and emerging process of meaning-reconstruction in bereavement research is theorized to lead to better psychological adjustment and prevent more prolonged grief reactions. The principal objective of this study is to compare two types of group counseling for individuals in bereavement: A novel meaning-based bereavement counseling group and a conventional bereavement support group.


Eligibility Criteria:
Inclusion Criteria:

* Individuals presenting for bereavement services that have experienced a death-related loss within 6 weeks to 2 years of the first meeting of the group, and are experiencing an uncomplicated grief response will be invited to participate.
* Individuals will be assessed for their ability to participate in a group counselling context as well as an uncomplicated grief trajectory. Participants must be 18 years of age or older, have sufficient ability to communicate in English, as well as read English.

Exclusion Criteria:

* Following a clinical/diagnostic interview and administration of the PG-13 (Prolonged Grief Disorder-13, Prigerson et al., 2009), individuals experiencing a complicated/prolonged grief trajectory are excluded.
* Furthermore, individuals whose cognitive condition might make the study burdensome or impossible for them are excluded.
Diagnostic Evaluation of the Tear Film

The objectives of this study are to assess for a difference between normal and dry eye subjects in tear film quality using a diagnostic interferometry device and to determine whether there are associations between tear film quality and dry eye symptoms and signs.


Eligibility Criteria:
Inclusion Criteria:

* Adults 18 year of age or older
* Willing and able to comply with study exam procedure

Exclusion Criteria:

* Eyelid abnormality or ocular surface condition affecting ability to visualize tear film
* Women who are pregnant or nursing
* Any of the following conditions within specified timeframe prior to study participation:

  1. Instillation of eye drops
  2. Contact lens wear
  3. Use of oil-based facial cosmetics
  4. Swimming in chlorinated pool
  5. Eye examination procedures that may affect the tear film
  6. Participation in another ophthalmic clinical trial
Neuronavigated TBS in Depression

In this randomized controlled trial we will treat 80 patients with depression with intermittent theta burst stimulation in two parallel arms. Both arms are active interventions differing with respect to positioning of the treatment coil - one arm with neuronavigation and one arm with targeting according to EEG Position representing the left dorsolateral prefrontal cortex. Randomisation will be balanced for in- and out-patients and for the treatment arms.

Intermittent Theta burst Stimulation (iTBS) is a specific type of repetitive transcranial magnetic Stimulation (rTMS). rTMS of the left prefrontal cortex was shown to be effective in the treatment of Depression. Recent studies showed that iTBS probably is as effective as rTMS.

One possibility to increase to efficacy of rTMS/iTBS is to use neuronavigation. With neuronavigation the coil Position can be targeted with an accuracy in the range of millimeters. Furthermore the Stimulation Position can be ensured during one single session and over the course of the daily Treatments.

The aim of the present study is to investigate the benefit of neuronavigation in the Treatment of Depression with iTBS by using two arms one with targeting the Stimulation site with neuronavigation and one by using the EEG Position F3 as target by using head caps for marking the position.

Eligibility Criteria:
Inclusion Criteria:

* unipolar or bipoloar depressive Episode according to ICD-10
* at least moderate Depression according to Hamilton Depression Rating Scale or ICD-10
* if applicable stable medication with psychoactive compounds for out-patients
* if applicable no or stable Treatment for Depression during the course of the Trial
* residence in Germany and mother tongue German
* written informed consent

Exclusion Criteria:

* Meeting the contraindications for transcranial magnetic Stimulation or magnetic resonance Imaging (electic devices or metal implants in the Body, e.g. cardiac pace maker, Insulin ppump)
* neurological disorders (e.g. cerebrovascular Events, neurodegenerative disorder, epilepsy, brain malformation, severe head Trauma)
* addictive disorder with consumption in the last two years
* regular intake of benzodiazepines
* participation in another study parallel to the Trial
* pregnancy or breastfeading period
* psychiatric confinement
Effect of Home Exercise Activity on Cortisol and Depression in COPD During the Pandemic COVID

exercise activity during the COVID pandemic is appreciated to be conducted in home especially for chronic chest diseases as chronic obstructive pulmonary disease (COPD) to reduce the chance of viral contamination during the COVID-19 pandemic.

40 COPD men will be divided to exercise group (20 patients) and control group (20 patients):

the exercise group will receive a exercise session contains a fifty minutes exercise training at home with moderate intensity on the available training devices as bicycle or treadmill in addition to 30 minutes of exercising of upper and lower limb, the session will be repeated three times per week for eight weeks.

The control group will not be trained

Eligibility Criteria:
Inclusion Criteria:

* stable COPD patients
* patients who will have a training device as bicycle or treadmill in home

Exclusion Criteria:

* diabetic patients
* renal patients.
* liver diseases
Docetaxel, Cisplatin, and Amifostine in Treating Patients With Advanced Non-small Cell Lung Cancer

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy.

PURPOSE: Phase I/II trial to study the effectiveness of combining docetaxel, cisplatin, and amifostine in treating patients who have advanced non-small cell lung cancer that cannot be surgically removed.

OBJECTIVES: I. Determine the maximum tolerated dose of docetaxel when combined with amifostine and high dose cisplatin in patients with advanced non-small cell lung cancer. II. Determine the response rate and survival of these patients treated with this regimen. III. Determine the tolerability of this regimen in these patients.

OUTLINE: This is a dose escalation, multicenter study of docetaxel. Patients receive amifostine IV over 15 minutes, immediately followed by docetaxel IV over 1 hour, followed at hour 2 by amifostine as above, immediately followed by high dose cisplatin IV over 30 minutes. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of patients receive escalating doses of docetaxel until the maximum tolerated dose is determined.

PROJECTED ACCRUAL: A total of 15-30 patients will be accrued for this study.

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically proven unresectable advanced non-small cell lung cancer Stable CNS metastases allowed

PATIENT CHARACTERISTICS: Age: Over 18 Performance status: ECOG 0 or 1 Life expectancy: Not specified Hematopoietic: WBC at least 3,500/mm3 Absolute neutrophil count at least 2,000/mm3 Platelet count at least 100,000/mm3 Hepatic: AST no greater than 2.5 times upper limit of normal (ULN) AND alkaline phosphatase no greater than ULN OR AST no greater than ULN AND alkaline phosphatase no greater than 4 times ULN Renal: Creatinine clearance at least 60 mL/min Other: Not pregnant Fertile patients must use effective contraception No peripheral neuropathy worse than grade 1

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Any type and any number of prior chemotherapy regimens allowed and recovered Greater than 3 months since prior cisplatin and recovered Endocrine therapy: Prior endocrine therapy allowed and recovered Radiotherapy: Prior radiotherapy allowed and recovered Surgery: Prior surgery allowed and recovered Other: No other concurrent medications which could cause renal injury
Pd-1 Antibody Combined Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer

Cervical cancer is one of the major health problems for chinese women. Besides surgery and radiotherapy, neoadjuvant chemotherapy has been proved to be an effective program by many studies. However, not all patients respond well to neoadjuvant chemotherapy. This is an open-label, single-arm, multi-center clinical trial to evaluate whether PD-1 in combination with neoadjuvant chemotherapy will achieve better objective response rate.

Subjects will receive therapy Q3W until evaluation of efficacy. The first cycle include cisplatin and albumin-bound paclitaxel. A combination of anti-PD-1 antibody (SHR-1210) with cisplatin and albumin-bound paclitaxel would be given in second and third cycles. Patients who have demonstrated complete or partial tumour responses （CR/PR）will receive surgery and receive postoperative adjuvant therapy in accordance with NCCN guideline. Patients who have demonstrated stable disease or progressive disease （SD/PD）will receive concurrent radiochemotherapy.

Eligibility Criteria:
Inclusion Criteria:

1. Patients with locally advanced (2018 FIGO staged IB3, IIA2 and IIB/IIIC1r（tumor size ≥ 4cm) ) cervical cancer and had not received any treatment before.
2. Histologically confirmed squamous carcinoma, adenocarcinoma or adenosquamous carcinoma of the cervix.
3. Pathological examination of the PD-L1 positive（Combined score Positive Score≥1）.
4. Females 18-70 years of age.
5. Eastern Cooperative Oncology Group score 0-1.
6. WBC≥3.5\*10\^9/L, NEU≥1.5\*10\^9/L, Platelet≥80×10\^9 /L; AST and ALT ≤1.5 times normal upper limit; Total bilirubin ≤1.5 times the upper limit of normal value; serum creatinine and blood urea nitrogen ≤the upper limit of normal value.
7. Well-compliance and willing to keep in touch.
8. Willing to participate in this study, and sign the informed consent.

Exclusion Criteria:

1. Active or known or suspected autoimmune disease requires a system treatment as follows but not limited to autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis, nephritis, hyperthyroidism, thyroid dysfunction, asthma requiring intervention with bronchodilators.
2. HIV infection, active HBV/HCV.
3. Condition requiring systemic treatment with small doses of corticosteroids within 1 months or large doses of corticosteroids within 3 months prior to randomization.
4. Any primary malignancy within 5 years.
5. Participate in other drug clinical trials at the same time.
6. Pregnant or lactating female patients.
7. Comorbidity including but not limited to: heart diseases (grade III-IV cardiac insufficiency (NYHA standard); central nervous system diseases or nonfunctional behavior; hematological system diseases; liver or kidney malformation or history of surgery.
8. Drug or alcohol abuse.
9. Unable or unwilling to sign informed consents.
10. Not eligible for the study judged by researchers.
Effectiveness of a Novel Concept for a Manual Toothbrush Broscyl®

The aim is to determine the efficacy and the satisfaction/adaptability of the manual Broscyl® toothbrush as compared with a standard " soft " manual toothbrush ADA (American Dental Association) reference using the modified Stillman brushing technique, in children, adults and elderly persons, after 3 months of daily use.


Eligibility Criteria:
Inclusion Criteria:

* Children attending school aged between 8 and 15 years
* OR adults aged from 18 to 45 years
* OR elderly persons aged more than 65 years old
* Presenting at least one incisive, one canine, one premolar and one molar in each quadrant
* Able to brush their own teeth at least twice a day
* Persons who have provided written informed consent
* Persons covered by the national health insurance agency

Exclusion Criteria:

* Persons with acute periodontal disease
* Persons in a period of postsurgical healing
* Persons with an acute oral pain syndrome
* Persons undergoing orthodontic treatment with a fixed brace
* Persons not covered by the national health insurance agency
* Pregnant women
* The use of adjuvants
Effects of a Manualized Short-term Treatment of Internet and Computer Game Addiction

The purpose of this study is to 1) determine the efficacy of manualized Short-term Treatment of Internet and Computer game Addiction (STICA), assess 2) the durability of treatment response in these patients and 3) the impact on associated psychiatric symptoms, e.g. social anxiety and depression.


Eligibility Criteria:
Inclusion Criteria:

* clinical diagnosis of internet or computer game addiction
* internet or computer game addiction according to the AICA-Checklist(Assessment of Internet and Computer game addiction, expert Rating)
* a score \>/= 7 in the AICA-S (Assessment of Internet and Computer game addiction, Self Rating)
* patients with primary diagnoses of internet or computer game addiction
* if currently on psychotropic medications, no change in medications and dosages in the past 2 months and during STICA treatment
* if currently off all psychotropic medications, patient has been off at least 4 weeks
* at least 4 weeks off from last psychotherapy and no other ongoing psychotherapy

Exclusion Criteria:

* current Global Assessment of Functioning (GAF) \< 40
* severe major depression (BDI-II Score \>/= 29)
* current alcohol or drug addictions
* personality disorders: borderline, antisocial, schizoid and schizotypal
* lifetime diagnoses of schizophrenia, schizoaffective, bipolar or organic mental disorder
* current unstable medical illness
Metabolomics of Roux-en-Y Gastric Bypass (RYGB) With Gastrostomy

This study is an investigation of the "metabolomics of RYGB with gastrostomy."

The rapid and durable remission of type II diabetes mellitis following the gastric bypass operation challenges the current concepts about the etiology of the disease. The surgery, which excludes food from the stomach, duodenum, and proximal jejunum, is quickly followed by a durable drop in glucose and insulin levels. As a result, 4 out of 5 diabetic, morbidly obese individuals who undergo the operation return to a long-term euglycemia with a prolongation of life and a reduction of health care costs.

The investigators at East Carolina University and those at Johnson and Johnson propose to further complete the profile of the upper gut by extending their observation to three additional human models. The investigators will study patients having the gastric band procedure, the gastric sleeve procedure, and those who have a gastric bypass but have a PEG tube inserted later.

Eligibility Criteria:
Inclusion Criteria:

* Female
* 18-60 years of age
* BMI of 35-65
* Willing to comply with study requirements and long term follow-up
* Capable of understanding the requirements and consequences of surgery and the study
* Is scheduled to have bariatric surgery performed
* Has a negative pregnancy test

Exclusion Criteria:

* Repeat gastric bypass procedure
* Patients who are unable to hold their insulin coverage for 48 hours prior to research visits
* Patients taking TZDs
Effects of Antimicrobial Photodynamic Therapy on Regeneration of Class II Furcation Lesions

The aim of this study is to evaluate the additional effect of antimicrobial photodynamic therapy regeneration treatment of mandibular furcation lesions when associated to bovine bone and porcine collagen membrane.


Eligibility Criteria:
Inclusion Criteria:

* Clinical diagnosis of class II furcation lesion in mandibular 1st and 2nd molars
* Mandibular 1st and 2nd molars without caries, erosion or abrasion

Exclusion Criteria:

* Smoking habit
* Pregnancy
* Use of antibiotics in the last six months
* Periodontal treatment in the last six months
* Endodontic lesion
* Systemic diseases that impair wound healing
Sperm Parameters and Sexual Quality of Life

Infertility has important repercussions for couples in their emotional and sexual lives; the same is true of Assisted Procreation, which has an impact on the daily life of couples and a cost to society. Thus, fertility disorders are frequently associated with sexual dysfunction in both women and men (Khademi et al., 2008). In couples with male infertility, men have higher sexual dysfunction scores than couples with infertility without male aetiology (Smith et al., 2009).

To study the evolution of the sexual quality of life of infertile men before and after knowing their spermatic parameters


Eligibility Criteria:
Inclusion Criteria:

* Male patient presenting infertility status

Exclusion Criteria:

* none